1. Home
  2. OMCL vs WVE Comparison

OMCL vs WVE Comparison

Compare OMCL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMCL
  • WVE
  • Stock Information
  • Founded
  • OMCL 1992
  • WVE 2012
  • Country
  • OMCL United States
  • WVE Singapore
  • Employees
  • OMCL N/A
  • WVE N/A
  • Industry
  • OMCL Computer Manufacturing
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • OMCL Technology
  • WVE Health Care
  • Exchange
  • OMCL Nasdaq
  • WVE Nasdaq
  • Market Cap
  • OMCL 2.0B
  • WVE 2.1B
  • IPO Year
  • OMCL 2001
  • WVE 2015
  • Fundamental
  • Price
  • OMCL $44.98
  • WVE $13.51
  • Analyst Decision
  • OMCL Buy
  • WVE Strong Buy
  • Analyst Count
  • OMCL 6
  • WVE 10
  • Target Price
  • OMCL $52.00
  • WVE $21.60
  • AVG Volume (30 Days)
  • OMCL 634.2K
  • WVE 1.1M
  • Earning Date
  • OMCL 02-06-2025
  • WVE 11-12-2024
  • Dividend Yield
  • OMCL N/A
  • WVE N/A
  • EPS Growth
  • OMCL N/A
  • WVE N/A
  • EPS
  • OMCL N/A
  • WVE N/A
  • Revenue
  • OMCL $1,064,205,999.00
  • WVE $53,610,000.00
  • Revenue This Year
  • OMCL N/A
  • WVE N/A
  • Revenue Next Year
  • OMCL $5.24
  • WVE $48.58
  • P/E Ratio
  • OMCL N/A
  • WVE N/A
  • Revenue Growth
  • OMCL N/A
  • WVE N/A
  • 52 Week Low
  • OMCL $25.12
  • WVE $3.50
  • 52 Week High
  • OMCL $55.75
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • OMCL 46.41
  • WVE 45.88
  • Support Level
  • OMCL $43.29
  • WVE $12.84
  • Resistance Level
  • OMCL $47.00
  • WVE $14.57
  • Average True Range (ATR)
  • OMCL 1.55
  • WVE 0.97
  • MACD
  • OMCL -0.27
  • WVE -0.24
  • Stochastic Oscillator
  • OMCL 37.31
  • WVE 23.26

About OMCL Omnicell Inc. ($0.001 par value)

Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: